What’s New in the Evolving Treatment Landscape
for Moderate-to Severe Atopic Dermatitis

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Spring Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 25, 2017 to August 1, 2018

Instructions for CME/CNE: Complete the pre test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This educational activity is supported by an educational grant from
Sanofi Genzyme and Regeneron Pharmaceuticals Alliance

Atopic dermatitis is a common chronic inflammatory skin disease characterized by persistent itching that can severely affect quality of life. This condition evolves from a combination of skin barrier defects and immune-mediated responses involving activated T-helper cells and related cytokines. Current atopic dermatitis treatments attempt to reduce inflammation and itchiness to maintain the protective integrity of the skin and have shown the ability to manage the disease in the short term, but have had troubles with long term efficacy. Fortunately, several new treatments, including novel monoclonal antibodies or targeted therapies, have shown improved efficacy and safety, offering patients the potential for improved outcomes and quality of life.

Upon Completion of this activity, participants will be able to:

  • Examine the mechanisms of action, efficacy, and safety of emerging therapies for moderate-to-severe atopic dermatitis (AD)

  • Apply approaches to treat patients with moderate-to-severe AD in the context of late-breaking data and patient-, disease-, and therapy-related factors

  • Analyze recent clinical data evaluating emerging targeted therapies for moderate-to-severe AD

  • Describe the immunopathogenic mechanisms of AD and the rationale for targeting the relevant cytokines

  • Discuss the epidemiology, disease burden, and quality-of-life dimensions associated with moderate-to-severe AD based on severity of disease and health care disparities

Faculty: Adelaide A. Hebert, MD
Professor of Dermatology and Pediatrics
The University of Texas Medical School - Houston


Dr. Hebert, through UTHealth McGovern Medical School, receives research funds from Anacor, Celgene, GlaxoSmithKline, Medimetrics and Merz; she is on the data safety monitoring board for GlaxoSmithKline, Regeneron/Sanofi and received honoraria from Anacor and GlaxoSmithKline. Her presentation has been peer reviewed.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Jacquelyn Smith has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation

The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This educational activity is supported by an educational grant from
Sanofi Genzyme and Regeneron Pharmaceuticals Alliance

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue